Bicara TherapeuticsBCAX +2.04%12 EV-to-EBIT is -8.07 as of Jul. 09, 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 366 Biotechnology companies, Bicara Therapeutics ranks worse than 273223.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bicara Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $765.42 Mil.
Bicara Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-174.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicara Therapeutics EV-to-EBIT Related Terms
Bicara Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bicara Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bicara Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicara Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bicara Therapeutics's EV-to-EBIT falls into.
Bicara Therapeutics's current Enterprise Value is $1,405.21 Mil.
Bicara Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-174.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicara Therapeutics (BCAX) has a EV-to-EBIT of -8.07 as of Jul. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bicara Therapeutics and its competitors. According to the industry distribution chart, Bicara Therapeutics ranks #999999 out of 366 companies in the Biotechnology industry.
Is Bicara Therapeutics' EV-to-EBIT too high?
Bicara Therapeutics' current EV-to-EBIT is -8.07. Based on the distribution chart, Bicara Therapeutics ranks #999999 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' EV-to-EBIT compare to ZYME and SRPT?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #999999 out of 366 companies for EV-to-EBIT. This places Bicara Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 14.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.63, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bicara Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicara Therapeutics's current EV-to-EBIT is -8.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current EV-to-EBIT of -8.07. The current EV-to-EBIT is -8.07. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current EV-to-EBIT is -8.07 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score
Get the complete analysis for BCAX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCAX has been successfully added to your 
